Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 1—January 2003
Perspective

Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

W. Michael Scheld*Comments to Author 
Author affiliation: *University of Virginia, School of Medicine, Charlottesville, Virginia, USA

Main Article

Table 4

Clinical failures of Streptococcus pneumoniae infection with levofloxacina

Risk factors
No. of cases
 Age
 Indication
 Coexisting conditions
 Prior FQ use
 Yr
 Ref.
 Country
1b
 58
 Meningitis
 HIV, splenectomy
 NR
 1999
 62
 USA
3
 NR
 RTI
Yes
 1999
 63
 USA
1
 63
 CAP
 COPD
 No
 1999
 64
 USA
1
 50
 CAP
 COPD
 No
 2000
 65
 USA
1
 84
 CAP
 COPD
 Yes-Levo
 2000
 65
 USA
1
 53
 HAP
 none
 No
 2001
 66
 USA
7
 39-83
(avg. 63)
 4 CAP
3 AECB
 COPD (5)
 5/7
(4-Lev, 1-Mox)
 2001
 67
 USA
1
 37
 CAP
 none
 No
 1999
 25
 Canada
1b
 66
 CAP
 COPD
 Yes-Cip +
Lev
 1999
 25
 Canada
1
 80
 AECB/CAP
 COPD,
 Yes-Cip
 2001
 25
 Canada
1
 64
 CAP
 none
 No
 2000
 25
 Canada
1
 50
 CAP
 COPD
 Yes-Lev
 2001
 68
 USA
1b
 79
 CAP
 none
 NO
 1999
 69
 USA
21
Clinical trials
13 (7 on 500 mg)
 NR
 AECB
 COPD
 No
70
 Neth.
4
 NR
 CAP
 NR
 No
71
 USA
24 (11)
Epidemiologic studies
16c
 -
 LRTI
 COPD
 Yes-Cip
 1995-96
 72
 Canada
27d
 -
 LRTI
 COPD (17)
 Yes-Lev
 1998-99
 73
 HK
43
Total 88 (74 on 500 mg) clinical/bacteriologic failures

aFQ, fluoroquinolone; NR, not reported; RTI, respiratory tract infection; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; Lev, levofloxacin; Mox, moxifloxacin; HAP, hospital-acquired pneumonia; AECB, acute exacerbation of chronic bronchitis;
LRTI, lower respiratory tract infection; Cip, ciprofloxacin; Neth, the Netherlands; HK, Hong Kong.
bDeath.
c3 deaths.
d4 deaths.

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external